Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Pamidronic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDPS known ✓ | P14324 | 19/20 | 0.78 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.71 |
| ▸ | LMNA | P02545 | 1/20 | 0.71 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.71 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.71 |
| ▸ | GGPS1 | O95749 | 8/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pamidronic Acid SCHEMBL18751 | 0.91 | FDPS (0.64) | FDPSPDE3ALMNAADRB3PDE4D | |
| Pamidronic Acid SCHEMBL506809 | 0.89 | FDPS (0.62) | FDPSPDE3ALMNAADRB3PDE4D | |
| Pamidronic Acid SCHEMBL4260287 | 0.89 | FDPS (0.62) | FDPSPDE3ALMNAADRB3PDE4D | |
| Alendronic Acid SCHEMBL328770 | 0.88 | FDPS (1.00) | FDPSPDE3ALMNAADRB3PDE4D | |
| Pamidronic Acid SCHEMBL570525 | 0.87 | FDPS (0.71) | FDPSPDE3ALMNAADRB3PDE4D | |
| Alendronic Acid SCHEMBL536412 | 0.86 | FDPS (0.96) | FDPSPDE3ALMNAADRB3PDE4D | |
| Alendronic Acid SCHEMBL3388 | 0.86 | FDPS (0.96) | FDPSPDE3ALMNAADRB3PDE4D | |
| Alendronic Acid SCHEMBL5973704 | 0.86 | FDPS (0.96) | FDPSPDE3ALMNAADRB3PDE4D | |
| Alendronic Acid SCHEMBL204535 | 0.86 | FDPS (0.96) | FDPSPDE3ALMNAADRB3PDE4D | |
| Alendronic Acid SCHEMBL3110183 | 0.86 | FDPS (0.96) | FDPSPDE3ALMNAADRB3PDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8916536-B2 | Bone-targeting bisphosphonate duplex drugs | SCHOTT HERBERT (DE) | 2014-12-23 | — | — | US | disclosed |
| EP-2601202-B1 | BONE-TARGETING BISPHOSPHONATE DUPLEX DRUGS | SCHOTT HERBERT (DE) | 2014-09-03 | — | — | EP | disclosed |
| US-20130237494-A1 | BONE-TARGETING BISPHOSPHONATE DUPLEX DRUGS | SCHOTT HERBERT (DE) | 2013-09-12 | — | — | US | disclosed |
| EP-2601202-A1 | BONE-TARGETING BISPHOSPHONATE DUPLEX DRUGS | SCHOTT, Herbert (DE) | 2013-06-12 | — | — | EP | disclosed |
| WO-2012016994-A1 | BONE-TARGETING BISPHOSPHONATE DUPLEX DRUGS | SCHOTT HERBERT (DE) | 2012-02-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130237494-A1 | BONE-TARGETING BISPHOSPHONATE DUPLEX DRUGS | BPGM, MVD, PPIP5K2 | FDPS 384/4885PDE3A 3238/4885LMNA 3664/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.